Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

43.69 +1.64 (+3.90%)
Streaming Delayed Price Updated: 3:16 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Xenon Pharmaceuticals's Earnings: A Preview ↗
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine ↗
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory... 
Via Benzinga
News headline image
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech ↗
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi... 
Via Benzinga
News headline image
Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile' ↗
More than half of high-dose patients reported a 50% decline in monthly seizures. 
Via Investor's Business Daily
News headline image
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment ↗
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More ↗
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week ↗
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
News headline image
Xenon Pharmaceuticals Has a Great Story But Too High a Price ↗
XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021 ↗
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
News headline image
Xenon: Heading Toward Phase III With Strong Momentum ↗
XENE stock is on solid footing after strong trial results 
Via InvestorPlace
News headline image
New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again ↗
XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again. 
Via InvestorPlace
News headline image
Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High ↗
Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80. Approximately 5.5 million shares have changed hands today, as compared to an... 
Via Benzinga
News headline image
3 Growth Stocks Near 52-Week Highs to Buy Anyway ↗
These top performers have what it takes to keep providing outsized gains for patient investors. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
News headline image
Xenon Pharmaceuticals Raises $300M Via Equity ↗
Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares... 
Via Benzinga
News headline image
Is Xenon Pharmaceuticals a Good Stock to Buy Now? ↗
Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher. 
Via The Motley Fool
News headline image
44 Biggest Movers From Yesterday ↗
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon ↗
Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild. 
Via InvestorPlace
News headline image
Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump ↗
Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
30 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
News headline image
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint ↗
Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mostly Lower; US Factory Orders Surpass Estimates ↗
Following the market opening Monday, the Dow traded down 0.01% to 34,326.18 while the NASDAQ fell 1.4% to 14,362.69. The S&P also fell, dropping 0.51% to 4,334.77. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Why Xenon Pharmaceuticals Stock Is Soaring Today ↗
Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
News headline image
Why Xenon Pharmaceuticals Stock Is Screaming Higher Today ↗
A positive mid-stage trial is powering this biotech stock higher today. 
Via The Motley Fool
News headline image
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q2 sales of $2.22 million. Earnings fell to a loss of $22.50 million, resulting in a 40.1% decrease from last... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.